- Home
- CHI vs COGT Comparison
CHI vs COGT Comparison
Compare CHI & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHI
- COGT
- Stock Information
- Founded
- CHI 2002
- COGT 2014
- Country
- CHI United States
- COGT United States
- Employees
- CHI N/A
- COGT N/A
- Industry
- CHI Investment Managers
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- CHI Finance
- COGT Health Care
- Exchange
- CHI Nasdaq
- COGT Nasdaq
- Market Cap
- CHI 910.4M
- COGT 900.3M
- IPO Year
- CHI N/A
- COGT 2018
- Fundamental
- Price
- CHI $12.00
- COGT $7.84
- Analyst Decision
- CHI
- COGT Buy
- Analyst Count
- CHI 0
- COGT 6
- Target Price
- CHI N/A
- COGT $14.20
- AVG Volume (30 Days)
- CHI 186.2K
- COGT 1.8M
- Earning Date
- CHI 01-01-0001
- COGT 11-12-2024
- Dividend Yield
- CHI 9.90%
- COGT N/A
- EPS Growth
- CHI N/A
- COGT N/A
- EPS
- CHI N/A
- COGT N/A
- Revenue
- CHI N/A
- COGT N/A
- Revenue This Year
- CHI N/A
- COGT N/A
- Revenue Next Year
- CHI N/A
- COGT N/A
- P/E Ratio
- CHI N/A
- COGT N/A
- Revenue Growth
- CHI N/A
- COGT N/A
- 52 Week Low
- CHI $9.70
- COGT $4.28
- 52 Week High
- CHI $11.61
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- CHI 51.53
- COGT 31.99
- Support Level
- CHI $11.70
- COGT $7.30
- Resistance Level
- CHI $12.19
- COGT $8.56
- Average True Range (ATR)
- CHI 0.19
- COGT 0.67
- MACD
- CHI -0.04
- COGT -0.08
- Stochastic Oscillator
- CHI 47.62
- COGT 16.77
About CHI Calamos Convertible Opportunities and Income Fund
CALAMOS CONVERTIBLE OPPORTUNITIES & INCOME FUND operates as a closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in convertible securities and high-yield securities.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.